September 12, 2008Preventing Medical Errors: Mixups between Insulin U-100 and U-500 (April 2008) Preventing Medical Errors: Mixups between Insulin U-100 and U-500 (April 2008)
This story originally aired in April 2008. In this special edition of FDA PSN, we are repeating some of the most important safety issues that continue to pose a public health concern. The Institute for Safe Medication Practices (ISMP) recently des... Tumor necrosis factor-α blockers (TNF blockers), Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab) Opportunistic infections are not consistently recognized in patients taking tumor necrosis factor-α blockers. Byetta (exenatide) UPDATE - Since October 2007, FDA has received reports of 6 cases of hemorrhagic or necrotizing pancreatitis in patients in taking Byetta. # posted by Network @ 1:00 PM
 |
Subscribe to Posts [Atom]